Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
- Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
- Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
- Associated Conditions
- Hyperphosphataemia
- Associated Therapies
- -
The Effects of Sevelamer Carbonate on Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Gary Striker
- Target Recruit Count
- 117
- Registration Number
- NCT01493050
- Locations
- 🇺🇸
Beth Israel Medical Center, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Vifor Pharma
- Target Recruit Count
- 659
- Registration Number
- NCT01464190
- Locations
- 🇧🇪
CHU Sart Tilman, Liege, Belgium
🇷🇴Dialmed Clinic SRL, Sibiu, Romania
🇩🇪KfH Nierenzentrum Berlin-Neukoelln, Berlin, Germany
Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Fresenius Medical Care North America
- Target Recruit Count
- 38
- Registration Number
- NCT01427907
- Locations
- 🇺🇸
Irving Place Dialysis Center, New York, New York, United States
🇺🇸North Haven Dialysis, North Haven, Connecticut, United States
🇺🇸Upper Manhattan Dialysis Clinic (UMDC), New York, New York, United States
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Vifor Pharma
- Target Recruit Count
- 1059
- Registration Number
- NCT01324128
- Locations
- 🇨🇿
Dialysis Centre Fresenius Medical Care, Sokolov, Czech Republic
🇩🇪KfH Nierenzentrum Berlin-Neukoelln, Berlin, Germany
🇷🇴Dialmed Clinic SRL, Sibiu, Romania
Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01308242
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4
- Conditions
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Albany College of Pharmacy and Health Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01277497
- Locations
- 🇺🇸
Albany Medical Center South Clinical Campus, Albany, New York, United States
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 98
- Registration Number
- NCT01220843
- Locations
- 🇫🇷
CHU de Nice Service de néphrologie, Nice, France
🇫🇷Hôpital Européen Georges Pompidou Service de Nephrologie, Paris, France
🇫🇷CHU St Etienne Hopital Nord Service de néphrologie, St Etienne, France
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Kenneth R. Phelps, M.D.
- Target Recruit Count
- 30
- Registration Number
- NCT01191762
- Locations
- 🇺🇸
Stratton Veterans Affairs Medical Center, Albany, New York, United States
Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 100
- Registration Number
- NCT01135615
- Locations
- 🇹🇷
Gulhane School of Medicine, Ankara, Turkey
Hypophosphatemic Rickets in Norway
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01057186
- Locations
- 🇳🇴
Haukeland University Hospital, Childrens departement, Bergen, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.